Fly News Breaks for August 7, 2019
HAE
Aug 7, 2019 | 06:28 EDT
JMP Securities analyst David Turkaly raised his price target on Haemonetics to $145 and kept his Outperform rating after its "strong" above-consensus Q2 results. The analyst believes that the company can generate "impressive" earnings growth over the coming years thanks to the volumes and pricing benefits coming from its Plasma division, as well as through margin expansion, share buybacks, and additional cost-saving initiatives.
News For HAE From the Last 2 Days
There are no results for your query HAE